Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine

GlobeNewswire12/20 22:00

Channel Therapeutics Announces It Achieved Its Endpoints In Two Pre-Clinical In Vivo Models Of Its Nerve Block Formulations For Acute Pain

Benzinga12/18 21:34

Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model

GlobeNewswire12/18 21:30

Why Poseida Therapeutics Shares Are Trading Higher By 219%; Here Are 20 Stocks Moving Premarket

Benzinga11/26 18:24

Chromocell Announces Name Change to "Channel Therapeutics Corporation" and Provides Therapeutic Program Updates

GlobeNewswire11/21 22:49

Chromocell Therapeutics | 10-Q：Q3 2024 四半期報告書

SEC11/14 05:37